HDAC6 and prostate cancer: Compound 2-75 is a promising enzalutamide hybrid with HDAC inhibitory activity, which induced p21, led to higher acetyl-tubulin levels (based on stronger HDAC6 inhibition) than vorinostat, and suppressed Hsp90 and AR protein levels in C4-2 prostate cancer cells[74].